Immunomodulatory therapy with glatiramer acetate reduces endoplasmic reticulum stress and mitochondrial dysfunction...

Area of Science:

• Neuroscience
• Immunology
• Cellular Biology

Background:

• Multiple sclerosis (MS) involves endoplasmic reticulum (ER) stress and mitochondrial dysfunction, contributing to neuronal loss.
• These cellular changes are observed in MS lesions and animal models like experimental autoimmune encephalomyelitis (EAE).

Purpose of the Study:

• To investigate if glatiramer acetate (GA) can mitigate ER stress and mitochondrial dysfunction in the spinal cords of chronic EAE mice.
• To explore the neuroprotective potential of immunomodulatory therapy in the context of MS pathology.

Main Methods:

• Routine histology and immunostaining were employed to assess spinal cord tissue.
• Electron microscopy was utilized to examine mitochondrial structure and ER.
• Analysis included evaluating inflammation, demyelination, ER stress markers, mitochondrial function, NAD+ pathway activity, and neuronal death.

Main Results:

• EAE mice exhibited significant inflammation, demyelination, mitochondrial dysfunction, ER stress, and neuronal death.
• A downregulation of NAD+-dependent pathways was observed in EAE spinal cords.
• GA treatment effectively reversed these pathological changes, including reducing ER stress and improving mitochondrial function.

Conclusions:

• Glatiramer acetate (GA) demonstrates efficacy in reversing key pathological hallmarks of experimental autoimmune encephalomyelitis (EAE).
• The findings suggest that immunomodulatory therapies like GA can exert indirect neuroprotective effects in the central nervous system (CNS) by modulating ER stress.
• GA's ability to alleviate cellular stress pathways offers a potential mechanism for its therapeutic benefit in multiple sclerosis (MS).